Insilico's AI-designed IPF drug rentosertib reverses predicted biological age, six aging clocks suggest

Rentosertib, Insilico Medicine's experimental oral drug for the incurable lung disease idiopathic pulmonary fibrosis (IPF), reduced patients' predicted biological age across six independently developed "aging clocks" in an analysis published September 7 in Nature Biotechnology. All six clocks, machine-learning models trained on blood-protein patterns, read treated patients as biologically younger than placebo recipients over the 12-week phase 2a trial. Coverage by The New York Times and Bloomberg pushed an r/singularity thread about the drug to roughly 900 upvotes within days.

What the Study Found

What is genuinely fresh is the aging analysis, not the lung data: Insilico reported rentosertib's lung-function results in 2025 and started a phase 3 trial in July 2026. The new paper ran Olink proteomic profiles of 2,841 proteins from 42 trial participants through six clocks — ProtAge, OrganAge, PAC, ipfP3GPT and PAOPAC — that agree in direction despite sharing neither features nor training data:

• Peak at week 4 in the 30 mg twice-daily arm: roughly three to four years of predicted biological age reduction (up to six years on one clock), plateauing by week 12.
• 21 of 54 drug-versus-placebo comparisons across clocks, doses and timepoints reached significance at a false-discovery-adjusted threshold below 0.10.
• The strongest aging signal came at 30 mg twice daily — a different dose from the best lung-function response (60 mg once daily), which the authors read as evidence the effect is not a mere byproduct of healthier lungs.
• Protein shifts were benchmarked against 55,319 UK Biobank profiles, which rentosertib appeared to push toward younger trajectories.

Why Phase 2a Is Not a Cure

"Predicted biological age" is a model readout of blood proteins, not measured lifespan or healthspan. The analysis covers 42 patients, is company-led, and reuses samples from a trial whose primary endpoint was safety; in the original 2025 Nature Medicine report, lung-function gains were secondary endpoints. The company's own commentary is hedged: Nobel laureate Michael Levitt, quoted in the press release, says what convinces him is cross-clock agreement, not effect size — and concedes the trial "cannot yet separate slower aging from a treated lung." The AI contribution deserves perspective too: PandaOmics flagged the TNIK target and generative chemistry designed the molecule — one accelerated step in a conventional pipeline whose drug, granted FDA orphan status in 2023, is approved nowhere.

What's Next

The decisive test is already running: a randomized, double-blind, placebo-controlled phase 3 study of about 320 patients at 47 centers in China, launched July 7, 2026, with the annual rate of decline in forced vital capacity as the primary endpoint over 52 weeks, a readout years away. Insilico's founder presented the work in Paris on September 8. The authors' next experiment: dosing healthy volunteers to see whether the signal survives outside a diseased lung. Until then, treat the three-year claims as an intriguing hypothesis, not a fountain of youth.